Abstract
Alzheimer's disease (AD) represents a considerable health and social problem. The pathogenesis of this multifactorial disease involves various events, among which amyloid beta (Aβ) protein brain accumulation and aggregation are crucial in triggering a cascade of neurotoxic events such as oxidative stress and neuroinflammation. The HYMBAD project focuses on the design and synthesis of new bio-hybrid molecules with a multi-target activity profile to tackle different Aβ-driven toxic events. In detail, scaffolds related to natural products namely chalcones and stilbenes, and polyoxometalates will be modified and conjugated with selected pharmacophores, among which are small peptide-like synthons and peptides containing the Aβ KLVFF motif. The biological evaluation of the hybrid bio-conjugates will assess their anti-inflammatory and antioxidant potentials (testing in vitro in microglial cells and in a Drosophila AD model), thereby enabling the development of novel agents for AD treatment.
Project details
Unibo Team Leader: Federica Belluti
Unibo involved Department/s:
Dipartimento di Farmacia e Biotecnologie
Coordinator:
Università degli Studi di PADOVA(Italy)
Total Unibo Contribution: Euro (EUR) 55.080,00
Project Duration in months: 24
Start Date:
16/10/2023
End Date:
28/02/2026
